BioCardia, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $15.3M
- Price
- $1.01
- % Change (Daily % change from the live per-ticker quote feed.)
- +4.44%
- Volume
- 82.5K
About
BioCardia, Inc. is a pioneering clinical-stage company dedicated to regenerative medicine, focusing on the development of advanced cellular and cell-derived therapies for a range of cardiac and respiratory ailments. Central to its pipeline is the CardiAMP Cell Therapy System, designed to address heart failure and chronic myocardial ischemia. Additionally, BioCardia is advancing an allogeneic cell therapy program, also targeting cardiac and pulmonary conditions. The company is further exploring a specific allogeneic cell therapeutic platform. This investigational treatment, derived from culture-expanded mesenchymal cells sourced from bone marrow, is currently undergoing Phase I/II trials for patients suffering from ischemic systolic heart failure. Beyond its therapeutic candidates, BioCardia also provides innovative delivery solutions. These include the Helix biotherapeutic delivery system, engineered to precisely administer treatments directly into the heart muscle via an internal penetrating helical needle, and a line of Morph deflectable guides and sheaths. BioCardia maintains its headquarters in Sunnyvale, California.
Quick stats
Shares outstanding15.1M
Computed float8.2M
Float / shares54.0%
Cash runway (months)4.5
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0000925741
Websitehttps://www.biocardia.com
AI Summary
AI-generated1/22
standardbullishearnings
BioCardia Reports Second Quarter 2026 Business Highlights and Financial Results
BioCardia received positive regulatory signals from Japan’s PMDA for its CardiAMP Cell Therapy and from the FDA regarding the sufficiency of its CardiAMP HF II trial for approval.
The FDA also indicated that DeNovo approval of its Helix delivery system is possible, while clinical data for CardiAMP in refractory angina showed improved exercise tolerance and reduced angina episodes.
Financially, the company narrowed its Q2 net loss to $1.6 million and raised $4.9 million via an ATM facility, ending the quarter with $4.1 million in cash to fund operations into 2027.
Red flags
- Cash runway extends only into 2027
- Raising capital via ATM facility